Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study

Michael R. Loebinger, Eva Polverino, James D. Chalmers, Harm A.W.M. Tiddens, Herman Goossens, Michael Tunney, Felix C. Ringshausen, Adam T. Hill, Rashidkhan Pathan, Gerhild Angyalosi, Francesco Blasi, Stuart J. Elborn, Charles S. Haworth

Source: Eur Respir J, 57 (1) 2001451; 10.1183/13993003.01451-2020
Journal Issue: January

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Michael R. Loebinger, Eva Polverino, James D. Chalmers, Harm A.W.M. Tiddens, Herman Goossens, Michael Tunney, Felix C. Ringshausen, Adam T. Hill, Rashidkhan Pathan, Gerhild Angyalosi, Francesco Blasi, Stuart J. Elborn, Charles S. Haworth. Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study. Eur Respir J, 57 (1) 2001451; 10.1183/13993003.01451-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: